[pubmed] Chemical synthesis and characterisation of the complement C5 inhibitory peptide zilucoplan
Posté : 05 janv. 2021 12:00
Amino Acids. 2021 Jan 4:1-5. doi: 10.1007/s00726-020-02921-5. Online ahead of print.
ABSTRACT
The complement component C5 inhibitory peptide zilucoplan is currently in phase III clinical trials for myasthenia gravis (MG). Despite being at an advanced stage of clinical development, there have been no published reports in the literature detailing its chemical synthesis. In this work, we describe an approach for the chemical synthesis of zilucoplan and validate that the synthesised compound blocks LPS-induced C5a production from human blood.
PMID:33398524 | PMC:PMC7781173 | DOI:10.1007/s00726-020-02921-5
Source: https://pubmed.ncbi.nlm.nih.gov/3339852 ... 9&v=2.14.2